The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

##STR00001##

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. ##STR00001##

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy. ##STR00001##

Treatment methods including administering a compound according to Formula (I)

##STR00001## Meta or para or a pharmaceutically acceptable salt thereof wherein: A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 are simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5) heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; SO.sub.2R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.

Treatment methods including administering a compound according to Formula (I)

##STR00001## Meta or para or a pharmaceutically acceptable salt thereof wherein: A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 are simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5) heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; SO.sub.2R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.

Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein X is O, S or NR.sup.5; or X is C(R.sup.6)C(R.sup.7), wherein the carbon atom bonded to R.sup.6 is also bonded to the carbon atom bonded to R.sup.4, and the carbon atom bonded to R.sup.7 is also bonded to the phenyl ring moiety in Formula 1; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, G and W are as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein X is O, S or NR.sup.5; or X is C(R.sup.6)C(R.sup.7), wherein the carbon atom bonded to R.sup.6 is also bonded to the carbon atom bonded to R.sup.4, and the carbon atom bonded to R.sup.7 is also bonded to the phenyl ring moiety in Formula 1; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, G and W are as defined in the disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Novel compounds according to Formula I ##STR00001##
Meta or para or a pharmaceutically acceptable salt thereof wherein:
A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 can be simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.

Novel compounds according to Formula I ##STR00001##
Meta or para or a pharmaceutically acceptable salt thereof wherein:
A.sub.11-A.sub.14 are N or CR.sub.11, CR.sub.12, CR.sub.13, CR.sub.14, respectively, with the proviso that no more than two of the four positions A in A.sub.11-A.sub.14 can be simultaneously N; A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 are N or CR.sub.6, CR.sub.7, CR.sub.8, CR.sub.9, CR.sub.10, respectively, with the proviso that at least one but no more than two of the five positions A in A.sub.6, A.sub.7, A.sub.8, A.sub.9, A.sub.10 is N; R.sub.1 is C(2-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1-3)alkyl)amino; R.sub.5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl; the sulfonyl group with R.sub.1 is represented by one of R.sub.7, R.sub.8 or R.sub.9; R.sub.15 is H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl; and R.sub.16 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkyl-C(1-3)alkyl.

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

##STR00001##